IranMiddle EastScience

‘Capability to Fight against British Coronavirus Unique Advantage of Iran-Made Vaccine’

The head of the production team of the Iranian coronavirus vaccine at the Headquarters for Executing the Order of Imam Khomeini says the vaccine, dubbed Coviran Barekat, works against the British variant of COVID-19.

“The coronavirus vaccine produced by Barekat Foundation is highly effective in fighting coronavirus,” Jahanpour said in an interview with the Persian-language Vatan-e Emrouz newspaper.

“The Iranian coronavirus vaccine has surprised the world because it is being manufactured in the best conditions and with very high quality and is in the final stages, and we hope that a mass production license will be issued in the middle of the third phase (of human trial) and it will be available in late spring next year,” he added.

“One of the advantages of the Iranian coronavirus vaccine compared to other vaccines in the world is its unique ability to affect the British virus mutation and it has been able to overcome the disease based on clinical tests,” Jahanpour said.

In relevant remarks on Saturday, senior member of Iran’s National Task Force for Fighting Coronavirus Minou Mohraz also said that the coronavirus vaccine produced by her country’s scientists has proved efficient in preventing the coronavirus mutations spreading in Britain and South Africa.

“The vaccine produced by the HEIKO is capable of fighting against the British coronavirus,” Mohraz, also a senior member of the team to assess the efficiency of the Iran-made vaccine, said.

She explained that the Iranian health ministry provided the HEIKO with a sample of the mutated virus which is 70% more viral than the normal coronavirus which makes it more lethal, and tests on the blood plasma of the first three volunteers who had received the Iran-made vaccine jabs showed 100% efficiency, meaning that all the mutated COVID-19 viruses have been killed.

Also, Head of the HEIKO’s Coronavirus Research Team Hassan Jalili said that “tests have shown that the blood plasma of the first people who were injected with Co-Iran Barekat vaccine in the clinical trial phase has been able to fully deactivate the mutated virus of the British coronavirus”.

Last Tuesday, Chairman of the HEIKO Mohammad Mokhber had also said that the country is the only producer of a vaccine which is effective on the coronavirus mutations spreading in Britain and South Africa.

“The only vaccine without side effects which is efficient on the mutated coronavirus is being developed by the HEIKO,” Mokhber said.

“The Equipment has been developed to produce 100,000 vaccine doses per month,” he added.

Mokhber noted that Iran has gone through 6 different project platforms to produce coronavirus vaccine with successful results, and said, “The clinical trial of one of the vaccines has started and three more will be completed by the end of the year.”

Mokhber said earlier this month that the first phase of human test for COVIRAN Barekat has been successful and no side effects have been reported from the vaccine.

“Two to three million doses of the vaccine will be produced in the country by the end of the current Iranian year (March 20),” he went on to say.

The official noted that the first phase of the human trial on 21 volunteers is about to finish, and added that the vaccine will be available to the public in spring.

“It will be given to people cheaper than the foreign sample and Iran will become self-sufficient in this field,” Mokhber stressed.

Earlier, Mokhber said that Iran has been among four countries acquiring know-how to manufacture COVID-19 vaccines, adding that medical success continued in the country despite the US sanctions.

After injecting the home-grown vaccine to the first volunteer, the World Health Organization (WHO) spokesperson welcomed Iranian success by saying, “WHO welcomes all vaccine development programs around the world.”

In relevant remarks earlier this month, Mohraz said that the Iran-made coronavirus vaccine which has been injected to 30 volunteers in 2 stages has not shown any side effects so far.

“The vaccine, which underwent its first test on January 29 and received the approval of the ethics committee, is under the supervision of me and two of my colleagues and is undergoing a clinical trial phase. Our goal in the first phase of the clinical trial is to evaluate the side effects and fortunately, the volunteers didn’t show any special side effects, and the vaccine was given to them for the second time,” the official said.

She noted that 30 people have received the vaccine so far , and said, “The vaccine is gradually being injected and after the approval of the assessment and supervising group, more volunteers will receive the testing shots.”

“Once the first phase proves successful, the second phase will continue with 300 volunteers,” Mohraz said.

Back to top button